“When you have a totally sales-motivated reason for doing CME, you should consider other options.” The return on investment for CME should be measured more in terms of improving public health than increasing script sales, asserted panelist Mark Deitch during the Pharmaceutical Alliance for CME section meeting at the Alliance for CME's annual conference in January. How does Deitch convince his clients of the value of CME? For one thing, when Deitch, a 20-year medical education veteran, ...

Register for Complete Access (Valid Email Required)

By registering on MeetingsNet now, you'll not only unlock the CONSULT Activist CME, you'll also gain access to exclusive premium content.

Already registered? here.